CN110812455A - A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application - Google Patents
A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application Download PDFInfo
- Publication number
- CN110812455A CN110812455A CN201911058036.4A CN201911058036A CN110812455A CN 110812455 A CN110812455 A CN 110812455A CN 201911058036 A CN201911058036 A CN 201911058036A CN 110812455 A CN110812455 A CN 110812455A
- Authority
- CN
- China
- Prior art keywords
- parts
- preparation
- essence
- raw materials
- taurine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 62
- 239000007788 liquid Substances 0.000 title claims abstract description 36
- 208000022531 anorexia Diseases 0.000 title claims abstract description 23
- 206010061428 decreased appetite Diseases 0.000 title claims abstract description 23
- 210000000952 spleen Anatomy 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 230000007812 deficiency Effects 0.000 claims abstract description 11
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 8
- 230000036039 immunity Effects 0.000 claims abstract description 8
- 208000002720 Malnutrition Diseases 0.000 claims abstract description 7
- 230000001071 malnutrition Effects 0.000 claims abstract description 7
- 235000000824 malnutrition Nutrition 0.000 claims abstract description 7
- 208000015380 nutritional deficiency disease Diseases 0.000 claims abstract description 7
- 206010037660 Pyrexia Diseases 0.000 claims abstract description 6
- 208000015181 infectious disease Diseases 0.000 claims abstract description 6
- 208000035415 Reinfection Diseases 0.000 claims abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 210000002345 respiratory system Anatomy 0.000 claims abstract description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 239000000463 material Substances 0.000 claims description 45
- 238000001914 filtration Methods 0.000 claims description 39
- 229960003080 taurine Drugs 0.000 claims description 36
- 239000002994 raw material Substances 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 29
- 239000008213 purified water Substances 0.000 claims description 27
- 239000000706 filtrate Substances 0.000 claims description 26
- 235000006533 astragalus Nutrition 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 18
- 239000003755 preservative agent Substances 0.000 claims description 18
- 230000002335 preservative effect Effects 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 240000007651 Rubus glaucus Species 0.000 claims description 17
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 17
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 17
- 240000001008 Dimocarpus longan Species 0.000 claims description 16
- 235000000235 Euphoria longan Nutrition 0.000 claims description 16
- 240000000950 Hippophae rhamnoides Species 0.000 claims description 14
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims description 14
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 13
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 13
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 13
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 13
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 13
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 13
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 13
- 240000000171 Crataegus monogyna Species 0.000 claims description 13
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 13
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 13
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 13
- 235000013355 food flavoring agent Nutrition 0.000 claims description 13
- 244000189799 Asimina triloba Species 0.000 claims description 12
- 235000006264 Asimina triloba Nutrition 0.000 claims description 12
- 241000045403 Astragalus propinquus Species 0.000 claims description 12
- 241000132012 Atractylodes Species 0.000 claims description 12
- 235000009467 Carica papaya Nutrition 0.000 claims description 12
- 241000007126 Codonopsis pilosula Species 0.000 claims description 12
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 12
- 235000017443 Hedysarum boreale Nutrition 0.000 claims description 12
- 235000007858 Hedysarum occidentale Nutrition 0.000 claims description 12
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 12
- 244000197580 Poria cocos Species 0.000 claims description 12
- 235000008599 Poria cocos Nutrition 0.000 claims description 12
- 239000007864 aqueous solution Substances 0.000 claims description 12
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 12
- 241001061264 Astragalus Species 0.000 claims description 11
- 240000005717 Dioscorea alata Species 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 210000004233 talus Anatomy 0.000 claims description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 7
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 7
- 240000006365 Vitis vinifera Species 0.000 claims description 7
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 7
- 241001523681 Dendrobium Species 0.000 claims description 6
- 239000005711 Benzoic acid Substances 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- 239000012982 microporous membrane Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000004576 sand Substances 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 4
- 229910021641 deionized water Inorganic materials 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 239000011148 porous material Substances 0.000 claims description 4
- 230000001376 precipitating effect Effects 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 230000004206 stomach function Effects 0.000 claims description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 244000144730 Amygdalus persica Species 0.000 claims description 2
- 235000005979 Citrus limon Nutrition 0.000 claims description 2
- 244000131522 Citrus pyriformis Species 0.000 claims description 2
- 244000241257 Cucumis melo Species 0.000 claims description 2
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims description 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 2
- 240000009088 Fragaria x ananassa Species 0.000 claims description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 2
- 239000004378 Glycyrrhizin Substances 0.000 claims description 2
- 241000229143 Hippophae Species 0.000 claims description 2
- 235000003935 Hippophae Nutrition 0.000 claims description 2
- 240000008790 Musa x paradisiaca Species 0.000 claims description 2
- 235000018290 Musa x paradisiaca Nutrition 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 2
- 239000004376 Sucralose Substances 0.000 claims description 2
- 240000000851 Vaccinium corymbosum Species 0.000 claims description 2
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 2
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 2
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims description 2
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 2
- 239000000619 acesulfame-K Substances 0.000 claims description 2
- 235000021014 blueberries Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 2
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 235000010199 sorbic acid Nutrition 0.000 claims description 2
- 239000004334 sorbic acid Substances 0.000 claims description 2
- 229940075582 sorbic acid Drugs 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 235000019408 sucralose Nutrition 0.000 claims description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 241000756943 Codonopsis Species 0.000 claims 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 24
- 239000003814 drug Substances 0.000 abstract description 13
- 230000006870 function Effects 0.000 abstract description 7
- 210000002784 stomach Anatomy 0.000 abstract description 7
- 230000029087 digestion Effects 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 230000036528 appetite Effects 0.000 description 15
- 235000019789 appetite Nutrition 0.000 description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 5
- 229930003268 Vitamin C Natural products 0.000 description 5
- 235000019154 vitamin C Nutrition 0.000 description 5
- 239000011718 vitamin C Substances 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000007012 clinical effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000023505 abnormal feces Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- -1 electuary Substances 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 206010016284 febrile convulsion Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 206010018388 glossodynia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/732—Chaenomeles, e.g. flowering quince
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8998—Hordeum (barley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a liquid oral preparation for treating children anorexia, monophagia and other diseases, and a preparation method and application thereof. Compared with the prior art, the traditional Chinese medicine composition has the effects of strengthening spleen and stomach, helping digestion and removing food stagnation, and has the functions of regulating the spleen and stomach, improving the immunity of the organism and improving the sub-health state of the organism. Treating infantile anorexia, monophagia, malnutrition, diarrhea due to spleen deficiency, fever, and recurrent infection of respiratory tract and digestive tract.
Description
Technical Field
The invention belongs to the technical development field of traditional Chinese medicines for children, and particularly relates to a liquid oral preparation for treating children anorexia, monophagia and other diseases, and a preparation method and application thereof.
Background
Anorexia is a common symptom in children, and is clinically characterized by long-time aversion to eating, reduced food consumption and slow increase of physical quality. The long course of disease may have adverse effects on the growth and development of children and intelligence development.
Acute upper respiratory infection is a common disease in pediatrics, can be caused by various viruses and bacteria, but is more than 90% of viruses, and has common symptoms of high fever, cough, appetite reduction, vomiting, diarrhea, dysphoria and even febrile convulsion. If the disease is not relieved or aggravated after 3-5 days, the infection may attack other parts. Especially, high fever is the main purpose of the parents to see a doctor, often causing the parents to be careless, but improper feeding is very easy to cause a series of feeding complications, and the survival rate of the children with the body quality is reduced.
Astragalus mongholicus and rhizoma picrorhizae residue granules collected and carried by the national drug standard (WS-5745(B-0745) -2014Z) are prepared from 11 medicines of astragalus mongholicus, rhizoma dioscoreae, honey-fried licorice root, poria cocos, dendrobe, fried malt, hawthorn, pawpaw, codonopsis pilosula, dried orange peel and bighead atractylodes rhizome, have the effects of strengthening spleen and stomach, tonifying qi and strengthening exterior to promote digestion, and promoting digestion and removing stagnation, and are used for improving symptoms such as anorexia, monophagia, hyperhidrosis, abnormal stool and susceptibility to cold caused by weakness of spleen and stomach and spleen failure in transportation.
Hippophae rhamnoides (the name of Latin, Hippophae rhamnoides Linn.) is a deciduous shrub of Hippophae of Elaeagnaceae, and contains carotene, alkaloid, fatty acid, vitamin C, etc., wherein the content of vitamin C is the highest, and the vitamin C is the name of vitamin C king. Can effectively regulate gastrointestinal functions; improving immunity, relieving cough and asthma, benefiting lung and eliminating phlegm.
The raspberry is the fruit of raspberry of Rosaceae, also called raspberry, contains abundant vitamin A, vitamin C and many minerals, and has high nutritive value and health care function. The immature Rubi fructus is processed to obtain Chinese medicinal material with effects of nourishing liver and kidney, replenishing essence and blood, consolidating constitution, and warming kidney yang. Modern researches show that because the raspberry contains a large amount of flavonoid substances, the raspberry not only has the effects of resisting bacteria, diminishing inflammation and resisting allergy, but also has the effects of enhancing immunity and resisting aging.
Longan is a food formed by drying longan, also known as fructus alpiniae oxyphyllae and arillus longan. The medicine has mild nature and sweet taste, contains thiamine, riboflavin, nicotinic acid, ascorbic acid and other chemical components, and has the effects of benefiting heart and spleen, tonifying qi and blood, tranquilizing, nourishing blood and preventing miscarriage. Is suitable for insomnia, amnesia, spleen deficiency, diarrhea, lassitude, asthenia, etc.
Taurine (Taurine, Tau), a sulfur-containing amino acid with simple structure in animal body, has the chemical name of 2-aminoethanesulfonic acid, is combined with cholic acid in human and animal bile, has the functions of anti-inflammation, antipyresis, analgesia, sedation, antibiosis, immunity enhancement and the like, and is mainly used for treating diseases such as bronchitis, tonsillitis, cold, fever, infantile spasm and the like clinically.
Disclosure of Invention
The invention relates to a liquid oral preparation for treating children anorexia, monophagia and other diseases, and a preparation method and application thereof, wherein 4 components of sea buckthorn, raspberry, longan and taurine are added in the formula of the liquid oral preparation according to the traditional Chinese medicine syndrome differentiation theory on the basis of astragalus root, dendrobium stem and hawthorn granules recorded in the national medicine standard (WS-5745(B-0745) -2014Z). Based on the original functions, the functions of regulating the spleen and stomach, promoting digestion and removing food stagnation are strengthened. The specific functions are as follows: has effects in regulating spleen and stomach function, enhancing immunity, and improving sub-health state of organism. Treating infantile anorexia, monophagia, malnutrition, diarrhea due to spleen deficiency, fever, and recurrent infection of respiratory tract and digestive tract.
The technical scheme for realizing the invention is as follows:
a liquid oral preparation for treating child anorexia and monophagia, and its preparing process and application are disclosed.
The raw materials comprise astragalus, common yam rhizome, honey-fried licorice root, poria cocos, dendrobium, fried malt, hawthorn, pawpaw, codonopsis pilosula, dried orange peel, bighead atractylodes rhizome, sea buckthorn, raspberry, longan and taurine.
The auxiliary materials comprise a flavoring agent, a preservative and essence.
The solvent comprises deionized water, purified water and distilled water.
The formula and the proportion are as follows:
the invention relates to a liquid oral preparation, which comprises the following components in parts by weight:
1.1, raw materials: 10-50 parts of astragalus membranaceus, 20-100 parts of common yam rhizome, 10-50 parts of honey-fried licorice root, 10-50 parts of poria cocos, 5-50 parts of dendrobium, 5-50 parts of roasted malt, 10-80 parts of hawthorn, 5-50 parts of pawpaw, 5-50 parts of codonopsis pilosula, 10-50 parts of dried orange peel, 5-50 parts of bighead atractylodes rhizome, 10-100 parts of sea buckthorn, 5-30 parts of raspberry, 5-50 parts of longan and 1-10 parts of taurine;
1.2 auxiliary materials: 800 portions of corrective 100, 0.1 to 50 portions of preservative and 0.5 to 5 portions of essence;
1.3 solvent: proper amount.
2. The method can also be as follows:
2.1, raw materials: 30 parts of astragalus membranaceus, 35 parts of common yam rhizome, 20 parts of honey-fried licorice root, 30 parts of poria cocos, 25 parts of dendrobe, 25 parts of fried malt, 32 parts of hawthorn, 25 parts of pawpaw, 28 parts of codonopsis pilosula, 20 parts of dried orange peel, 30 parts of bighead atractylodes rhizome, 35 parts of sea buckthorn, 20 parts of raspberry, 30 parts of longan and 5 parts of taurine;
2.2 auxiliary materials: 700 portions of corrective 200 and preservative, 0.2-40 portions of preservative and 0.5-4 portions of essence;
2.3 solvent: proper amount.
3. The method can also be as follows:
3.1 raw materials: 10-50 parts of astragalus membranaceus, 20-100 parts of common yam rhizome, 10-50 parts of honey-fried licorice root, 10-50 parts of poria cocos, 5-50 parts of dendrobium, 5-50 parts of roasted malt, 10-80 parts of hawthorn, 5-50 parts of pawpaw, 5-50 parts of codonopsis pilosula, 10-50 parts of dried orange peel, 5-50 parts of bighead atractylodes rhizome, 10-100 parts of sea buckthorn, 5-30 parts of raspberry, 5-50 parts of longan and 1-10 parts of taurine;
3.2 auxiliary materials: 1-50 parts of corrigent, 0.1-50 parts of preservative and 0.5-5 parts of essence;
3.3 solvent: proper amount.
4. The method can also be as follows:
4.1 raw materials: 30 parts of astragalus membranaceus, 35 parts of common yam rhizome, 20 parts of honey-fried licorice root, 30 parts of poria cocos, 25 parts of dendrobe, 25 parts of fried malt, 32 parts of hawthorn, 25 parts of pawpaw, 28 parts of codonopsis pilosula, 20 parts of dried orange peel, 30 parts of bighead atractylodes rhizome, 35 parts of sea buckthorn, 20 parts of raspberry, 30 parts of longan and 5 parts of taurine;
4.2 auxiliary materials: 1-50 parts of corrigent, 0.1-50 parts of preservative and 0.5-5 parts of essence;
4.3 solvent: proper amount.
The flavoring agent in the formula and the proportion 1 or 2 is cane sugar.
The flavoring agent in the formula and the proportion 3 or 4 comprises any one or more of steviosin, aspartame, acesulfame potassium, aspartame, glycyrrhizin, neotame and sucralose.
The preservative in the formula and the proportion 1-4 comprises any one or mixture of more of benzoic acid, sorbic acid and salts thereof;
the essence in the formula and the proportion 1-4 comprises any one or more of lemon essence, juicy peach essence, Hami melon essence, grape essence, miscellaneous fruit essence, blueberry essence, banana essence, strawberry essence and orange essence.
The solvent in the formula and the proportion of 1-4 comprises purified water, deionized water and distilled water.
Secondly, the preparation method comprises the following steps:
1. preparation method 1 (sugar-containing oral liquid preparation):
taking the raw materials, the auxiliary materials and the solvent in the formula and the proportion 1 or 2, and preparing the raw materials, the auxiliary materials and the solvent according to the following method;
1.1, taking taurine, adding a small amount of purified water for dissolving to obtain a taurine aqueous solution for later use;
1.2 taking the other 13 medicinal materials such as astragalus and the like, adding water for decoction twice, adding 10-12 times of water for the first time, decocting for 2-3 hours, adding 8-10 times of water for the second time, decocting for 1-2 hours, combining decoction liquids of the two times, filtering, standing the filtrate for 20-40 hours, taking supernate for filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.2-1.3 at 55-60 ℃, and obtaining the extract of the medicinal materials such as the astragalus and the like for later use;
1.3 extracting the medicinal materials such as the astragalus and the like to obtain clear paste, adding ethanol to ensure that the ethanol content is 60-80%, stirring for 15-30 minutes, standing for 18-24 hours at the temperature of 3-25 ℃, taking supernatant, filtering, recovering ethanol from filtrate until no ethanol smell exists, and concentrating to obtain thick paste with the relative density of 1.25-1.35 at the temperature of 55-60 ℃ to obtain alcohol precipitation thick paste for later use;
1.4 taking the flavoring agent, the preservative and the essence, adding a small amount of purified water for dissolving, and filtering to obtain a dissolving solution of auxiliary materials such as the flavoring agent for standby;
1.5 taking the thick paste, adding taurine aqueous solution, flavoring agent and other auxiliary material dissolved solutions, adding purified water to 70-80% of the preparation amount, stirring for dissolving, standing for 18-24 hours, filtering, adding purified water to the filtrate to the preparation amount, stirring for 15-30 minutes, filling and sterilizing to obtain the finished product.
2. Preparation method 2 (sugar-free liquid oral liquid preparation):
taking the formula and the raw materials, auxiliary materials and solvents in the mixture ratio of 3 or 4, and preparing the mixture according to the following method;
2.1, adding a small amount of purified water into taurine to dissolve the taurine to obtain a taurine aqueous solution for later use;
2.2, taking the rest 13 raw materials such as astragalus and the like, adding water for decocting twice, adding 10-12 times of water for decocting for 2-3 hours for the first time, adding 8-10 times of water for decocting for 1-2 hours for the second time, combining the decoctions for two times, filtering, standing the filtrate for 18-24 hours, taking the supernatant, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.2-1.3 at 55-60 ℃ to obtain the extract of the medicinal materials such as the astragalus and the like for later use;
2.3, extracting the medicinal materials such as the astragalus and the like to obtain clear paste, adding ethanol to ensure that the ethanol content is 60-75 ℃, stirring for 30 minutes, standing for 18-24 hours at the temperature of 5-7 ℃, taking supernatant, filtering, recovering ethanol from filtrate until no ethanol smell exists, and concentrating to obtain thick paste with the relative density of 1.25-1.35 at the temperature of 55-60 ℃ to obtain alcohol precipitation thick paste for later use;
2.4, taking the flavoring agent, the preservative and the essence, adding a small amount of purified water for dissolving, filtering, and obtaining filtrate for later use;
2.5, adding the taurine aqueous solution and the filtrate into the ethanol precipitation thick paste, adding purified water to reach 70-80% of the preparation amount, stirring for 30 minutes, adding purified water to reach the preparation amount, stirring uniformly, filtering, filling, and performing moist heat sterilization at 105 ℃ for 45 minutes to obtain the taurine-containing soft extract.
The filtration in the preparation method 1.2 or 2.2 refers to the filtration by using a 100-sand 250-mesh stainless steel screen.
The filtration in the preparation method 1.3 or 2.3 refers to the filtration by a sand filter stick or a ceramic filter stick or a filter felt with the aperture of 0.8 mu m.
The filtration of the preparation method 1.4, 1.5, 2.4 or 2.5 refers to the filtration by a microporous membrane with the aperture of 0.45-0.68 μm.
The sterilization in the preparation method 1.5 or 2.5 refers to the sterilization by moist heat at 105 ℃ for 45 minutes or the sterilization by moist heat at 121 ℃ for 25 minutes, and the liquid oral preparation also comprises dosage forms such as oral liquid, suspension or syrup and the like.
The invention can also be prepared into solid preparation formulations such as electuary, tablets, capsules and the like.
The application of the invention is as follows: can regulate spleen and stomach function, improve immunity, improve sub-health state of organism, and treat infantile anorexia, monophagia, malnutrition, diarrhea due to spleen deficiency, fever, and recurrent infection of respiratory tract and digestive tract.
Advantageous effects
The invention relates to a liquid oral preparation for treating children anorexia, monophagia and other diseases, and a preparation method and application thereof. Compared with the prior art, the traditional Chinese medicine composition has the effects of strengthening spleen and stomach, helping digestion and removing food stagnation, and has the functions of regulating the spleen and stomach, improving the immunity of the organism and improving the sub-health state of the organism. Treating infantile anorexia, monophagia, malnutrition, diarrhea due to spleen deficiency, fever, and recurrent infection of respiratory tract and digestive tract.
Detailed Description
The following examples further describe and demonstrate embodiments within the scope of the present invention and are presented for illustrative purposes and are not to be construed as limiting the invention.
The following are various illustrative, non-limiting examples of liquid oral formulations of the present invention.
Example 1 (preparation 1000ml)
Raw materials: 30 parts of astragalus membranaceus, 35 parts of common yam rhizome, 20 parts of honey-fried licorice root, 30 parts of poria cocos, 25 parts of dendrobe, 25 parts of fried malt, 32 parts of hawthorn, 25 parts of pawpaw, 28 parts of codonopsis pilosula, 20 parts of dried orange peel, 30 parts of bighead atractylodes rhizome, 35 parts of sea buckthorn, 20 parts of raspberry, 30 parts of longan and 5 parts of taurine;
auxiliary materials: 400 parts of cane sugar, 10 parts of sodium benzoate and 1 part of grape essence;
solvent: and (5) purifying the water.
The preparation method comprises the following steps:
1. dissolving taurine in a small amount of purified water to obtain a taurine aqueous solution for later use;
2. decocting the rest 13 materials such as radix astragali in water twice, adding 12 times of water for the first time, decocting for 2.5 hr, adding 8 times of water for the second time, decocting for 1 hr, mixing decoctions, filtering with 250 mesh sieve, standing for 24 hr, collecting supernatant, filtering with 250 mesh sieve, concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.2-1.3 at 55-60 deg.C, and collecting fluid extract of radix astragali;
3. extracting the above medicinal materials such as radix astragali, etc. to obtain fluid extract, adding ethanol to make ethanol content at 75 deg.C, stirring for 30 min, standing at 5-7 deg.C for 24 hr, collecting supernatant, filtering with 0.60 μm sand filter stick, recovering ethanol from filtrate until no ethanol smell exists, concentrating to obtain soft extract with relative density of 1.25-1.35 at 55-60 deg.C, and precipitating with ethanol to obtain soft extract;
4. dissolving sucrose, sodium benzoate and grape essence in small amount of purified water, filtering with microporous filter membrane with pore diameter of 0.60 μm, and collecting filtrate;
5. mixing the above soft extract with taurine aqueous solution and filtrate, adding purified water to 70-80% of the preparation amount, stirring for 30 min, adding purified water to 1000ml, stirring, filtering with 0.60 μm microporous membrane, bottling, and sterilizing at 105 deg.C for 45 min.
Example 2 (preparation 1000ml)
Raw materials: 30 parts of astragalus membranaceus, 35 parts of common yam rhizome, 20 parts of honey-fried licorice root, 30 parts of poria cocos, 25 parts of dendrobe, 25 parts of fried malt, 32 parts of hawthorn, 25 parts of pawpaw, 28 parts of codonopsis pilosula, 20 parts of dried orange peel, 30 parts of bighead atractylodes rhizome, 35 parts of sea buckthorn, 20 parts of raspberry, 30 parts of longan and 5 parts of taurine;
auxiliary materials: 3 parts of steviosin, 5 parts of benzoic acid and 1 part of grape essence;
solvent: and (5) purifying the water.
The preparation method comprises the following steps:
dissolving taurine in a small amount of purified water to obtain a taurine aqueous solution for later use;
decocting the rest 13 medicinal materials such as radix astragali in water twice, adding 12 times of water for the first time, decocting for 2 hr, adding 8 times of water for the second time, decocting for 1.5 hr, mixing decoctions, filtering with 250 mesh sieve, standing for 24 hr, collecting supernatant, filtering with 250 mesh sieve, and concentrating the filtrate under reduced pressure to obtain fluid extract with relative density of 1.2-1.3 at 55-60 deg.C, to obtain fluid extract of radix astragali;
extracting the above medicinal materials such as radix astragali, etc. to obtain fluid extract, adding ethanol to make ethanol content at 75 deg.C, stirring for 30 min, standing at 5-7 deg.C for 24 hr, collecting supernatant, filtering with 0.60 μm sand filter stick, recovering ethanol from filtrate until no ethanol smell exists, concentrating to obtain soft extract with relative density of 1.25-1.35 at 55-60 deg.C, and precipitating with ethanol to obtain soft extract;
dissolving steviosin, benzoic acid and grape essence with small amount of purified water, filtering with microporous membrane with pore diameter of 0.60 μm, and collecting filtrate;
mixing the above soft extract with taurine aqueous solution and filtrate, adding purified water to 70-80% of the preparation amount, stirring for 30 min, adding water to 1000ml, stirring, filtering with 0.60 μm microporous membrane, bottling, and sterilizing at 120 deg.C for 25 min.
Example 3
The liquid oral preparation prepared in the embodiment 2 of the invention is used for treating 50 cases of child anorexia.
1. Patient screening:
50 children patients with anorexia and spleen deficiency syndrome differentiation of traditional Chinese medicine are selected and divided into 2 groups according to a random table. The treatment groups comprise 25 cases, 2-3 years old and 5 cases, 3-5 years old and 28 cases, and 17 cases above 5 years old; the statistical calculation shows that 50 cases of the control group, 7 cases of 2-3 years old, 30 cases of 3-5 years old and 13 cases of 6 years old are: the difference is not statistically significant (P > 0.05) and is comparable.
2. Diagnostic criteria:
referring to the diagnosis standard of anorexia of traditional Chinese medicine pediatrics: (1) anorexia and food consumption reduction for a long time without other diseases; (2) the complexion is lusterless, the body is emaciated, but the spirit is still good; (3) there is a history of feeding, such as irregular and quantitative eating, overeating raw or cold food, sweet and thick taste, snacks, or monophagia, etc.; (4) dislike of food intake, poor appetite or occasional polyphagia with abdominal distention, abnormal stool, good spirit, pale red tongue with white greasy or yellowish coating, soft-superficial, slow or smooth and rapid pulse. The spleen-stomach qi deficiency type symptoms are as follows: poor appetite, emaciation, poor appetite, scanty and more stool, lusterless complexion, lassitude, easy sweating, susceptibility to cold, swollen and tender tongue, pale tongue with thin and white coating, and slow and weak pulse.
3. The treatment method comprises the following steps:
treatment groups orally administered the liquid oral formulation obtained in example 2 of the present invention: 1 to 3 years old, 5ml for 1 time and 3 times for 1 day; 1 time after 3-5 years old and 10ml for 1 time, and 3 times after 1 day; 20ml for 1 time and 3 times for 1 day above 6 years old. 1 week is 1 course of treatment, and 2 courses of continuous administration; the control group was administered with the oral liquid of lactobacillin tablet and zinc gluconate for the same treatment period of 1.3.
Statistical treatment: by X2The data are statistically analyzed by the test, and P is less than 0.05, thus having statistical significance.
4. The treatment results are as follows:
the therapeutic effect judgment standard is as follows: according to the standard for diagnosing the common diseases and judging the curative effect, the traditional Chinese medicine has the following effects: the appetite is obviously recovered, the appetite is recovered to 3/4 of the original level, and the original symptoms are basically disappeared; the method has the following advantages: improving appetite, recovering appetite, but not reaching 3/4 of original level, and relieving original symptoms; and (4) invalidation: the appetite and the food intake are not improved, and the results of the clinical curative effects of the two groups are shown in table 1.
Table 1: comparison of clinical effects of two groups
Group of | Number of cases | Show effect | Is effective | Invalidation | Total effective rate (%) |
Treatment group | 25 | 15 | 9 | 1 | 96 |
Control group | 25 | 8 | 12 | 6 | 80 |
The curative effect of the two groups of curative effect comparison treatment groups is better than that of the control group, and the difference has statistical significance (P is less than 0.01).
Example 4
The liquid oral preparation prepared in the embodiment 2 of the invention is used for observing the curative effect of treating the children malnutrition.
1. Patient screening:
67 cases of children with malnutrition of 2-7 years old were selected and randomly divided into a treatment group and a control group, and 36 cases of the treatment group and 31 cases of the control group. The treatment groups were 15 men and 21 women; the control group comprises 20 male and 11 female.
2. The treatment method comprises the following steps:
the control group is subjected to general symptomatic treatment, and the liquid oral preparation obtained in the example 2 of the invention is orally taken by the treatment group, 10ml is taken every time after the age of 2-4 years, and 3 times are taken every day; 20ml for 4-7 years old, 3 times per day for 8 weeks. During the test period, the appetite and appetite improvement of the infant patients were recorded every week. Body weight was measured before and 6 months after treatment to understand the change in body weight.
3. The therapeutic effect judgment standard is as follows:
the effect is obvious, and the weight of the treated patient reaches the standard in the observation period; the medicine is effective, the disease incidence frequency is reduced by 50% after treatment, and the weight reaches the standard after treatment; the body weight is not reached after treatment without effect.
The statistical method comprises the following steps:
the measured data are expressed as mean. + -. standard deviation (x. + -.s), and the two-by-two comparison is performed by using t-test.
4. The treatment results are as follows: the clinical effects of the two groups are compared and shown in Table 2.
Table 2: comparison of clinical effects of two groups
Group of | Number of cases | Show effect | Is effective | Invalidation | Total effective rate (%) | p |
Treatment group | 36 | 18 | 13 | 5 | 86.11 | <0.01 |
Control group | 31 | 1 | 15 | 16 | 51.61 | <0.01 |
After the treatment, the appetite of the children patients is obviously improved, and the total effective rate is 86.11 percent, so that the appetite of the children patients is recovered to be normal. While the control group of children patients only improve the appetite by 16 percent, and the total effective rate is 51.61 percent.
Example 5
The liquid oral preparation prepared in the embodiment 2 of the invention is used for treating infantile diarrhea caused by spleen deficiency.
1. Diagnostic criteria: refer to the diagnosis standard of 'the complete book of pediatric diagnosis and treatment in modern traditional Chinese medicine'.
2. Patient screening:
according to the above standards, 78 outpatient children with spleen deficiency syndrome were randomly divided into 56 treatment groups and 22 control groups for 1-6 months. The treatment groups were 38 men and 18 women; the control group comprises 14 men and 8 women. The treatment groups had a minimum age of 2 years, a maximum age of 7 years, and an average age of 4.3 years; the control group had a minimum age of 9 months and a maximum age of 8 years, with an average age of 6.2 years. The difference between the two groups of ages is not significant (P > 0.05).
3. Method of treatment
The treatment group takes the oral liquid preparation prepared in the embodiment 2 orally, the age is 2-4 years, 5ml is taken every time, and 3 times are taken every day; 5-7 years old, 10 ml/time, 3 times/day. The contrast group orally takes the lactobacillus tablets for 9 months to 3 years old, 0.5 ml/day and 3 times/day; 10 ml/time for 4-8 years old, 3 times/day. Two groups take 7 days as a treatment course, and 2 treatment courses are continuously observed.
4. Clinical efficacy evaluation criteria
The Chinese medicinal composition is cured according to the 'diagnosis and treatment effect standard of the internal and external gynecologic and pediatric diseases of traditional Chinese medicine' formulated by the State administration of medical science and government (1): the excrement is taken 1 time every day, the formed soft excrement has no mucus, the general symptoms disappear, the appetite is improved, and the excrement is not abnormal in microscopic examination; (2) the effect is shown: the stool frequency is obviously reduced to below 1/3 before treatment, the stool is shaped or soft, and the general symptoms and the stool microscopic examination are obviously improved; (3) the method has the following advantages: the stool frequency is reduced to 1/2 before treatment, and the shape, symptoms and stool microscopic examination are improved; (4) and (4) invalidation: the times and shape of the stool are not improved, and the stool is still abnormal in microscopic examination.
5. The treatment results are as follows: the two groups of therapeutic effects are compared and shown in Table 3.
TABLE 3
Group of | Number of cases | Recovery method | Show effect | Is effective | Invalidation | Total effective rate |
Treatment group | 56 | 18 | 22 | 15 | 1 | 98.22 |
Control group | 22 | 1 | 3 | 12 | 6 | 72.72 |
Through statistical treatment and analysis, the treatment group is superior to the control group in the aspects of total effective rate, cure rate and significant efficiency, which shows that the liquid oral preparation prepared by the invention has definite curative effect on the infantile spleen deficiency diarrhea.
Description of the drawings: examples 3 to 5 above were assigned to the inner Mongolia hospital for clinical trials.
Claims (20)
1. A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application are disclosed, wherein the preparation comprises raw materials including radix astragali, rhizoma Dioscoreae, radix Glycyrrhizae Preparata, Poria, herba Dendrobii, fructus Hordei Germinatus preparata, fructus crataegi, fructus Chaenomelis, radix Codonopsis, pericarpium Citri Tangerinae, Atractylodis rhizoma, fructus Hippophae, Rubi fructus, arillus longan, and taurine; the auxiliary materials comprise a flavoring agent, a preservative and essence; the solvent comprises deionized water, purified water and distilled water.
2. The raw materials, the auxiliary materials and a proper amount of solvent according to claim 1, wherein the formula and the mixture ratio are as follows by weight:
2.1, raw materials: 10-50 parts of astragalus membranaceus, 20-100 parts of common yam rhizome, 10-50 parts of honey-fried licorice root, 10-50 parts of poria cocos, 5-50 parts of dendrobium, 5-50 parts of roasted malt, 10-80 parts of hawthorn, 5-50 parts of pawpaw, 5-50 parts of codonopsis pilosula, 10-50 parts of dried orange peel, 5-50 parts of bighead atractylodes rhizome, 10-100 parts of sea buckthorn, 5-30 parts of raspberry, 5-50 parts of longan and 1-10 parts of taurine;
2.2 auxiliary materials: 800 portions of corrective 100, 0.1 to 50 portions of preservative and 0.5 to 5 portions of essence;
2.3 solvent: proper amount.
3. The raw materials, the auxiliary materials and a proper amount of solvent according to claim 2, wherein the formula and the mixture ratio thereof are as follows by weight:
3.1 raw materials: 30 parts of astragalus membranaceus, 35 parts of common yam rhizome, 20 parts of honey-fried licorice root, 30 parts of poria cocos, 25 parts of dendrobe, 25 parts of fried malt, 32 parts of hawthorn, 25 parts of pawpaw, 28 parts of codonopsis pilosula, 20 parts of dried orange peel, 30 parts of bighead atractylodes rhizome, 35 parts of sea buckthorn, 20 parts of raspberry, 30 parts of longan and 5 parts of taurine;
3.2 auxiliary materials: 700 portions of corrective 200 and preservative, 0.2-40 portions of preservative and 0.5-4 portions of essence;
3.3 solvent: proper amount.
4. The raw materials, the auxiliary materials and a proper amount of solvent according to claim 1, wherein the formula and the mixture ratio by weight are as follows:
4.1 raw materials: 10-50 parts of astragalus membranaceus, 20-100 parts of common yam rhizome, 10-50 parts of honey-fried licorice root, 10-50 parts of poria cocos, 5-50 parts of dendrobium, 5-50 parts of roasted malt, 10-80 parts of hawthorn, 5-50 parts of pawpaw, 5-50 parts of codonopsis pilosula, 10-50 parts of dried orange peel, 5-50 parts of bighead atractylodes rhizome, 10-100 parts of sea buckthorn, 5-30 parts of raspberry, 5-50 parts of longan and 1-10 parts of taurine;
4.2 auxiliary materials: 1-50 parts of corrigent, 0.1-50 parts of preservative and 0.5-5 parts of essence;
4.3 solvent: proper amount.
5. The raw materials, the auxiliary materials and a proper amount of solvent according to claim 4, wherein the formula and the mixture ratio by weight are as follows:
5.1, raw materials: 30 parts of astragalus membranaceus, 35 parts of common yam rhizome, 20 parts of honey-fried licorice root, 30 parts of poria cocos, 25 parts of dendrobe, 25 parts of fried malt, 32 parts of hawthorn, 25 parts of pawpaw, 28 parts of codonopsis pilosula, 20 parts of dried orange peel, 30 parts of bighead atractylodes rhizome, 35 parts of sea buckthorn, 20 parts of raspberry, 30 parts of longan and 5 parts of taurine;
5.2 auxiliary materials: 1-50 parts of corrigent, 0.1-50 parts of preservative and 0.5-5 parts of essence; 3 parts of steviosin, 5 parts of benzoic acid and 1 part of grape essence;
5.3 solvent: proper amount.
6. The raw materials, the auxiliary materials and a proper amount of solvent according to claim 2 or 3, characterized in that the flavoring agent is sucrose.
7. The raw materials, the auxiliary materials and a proper amount of solvent according to claim 4 or 5, characterized in that the flavoring agent comprises any one or more of steviosin, aspartame, acesulfame-K, aspartame, glycyrrhizin, neotame and sucralose.
8. The raw materials, auxiliary materials and appropriate amount of solvent according to claims 1-5, characterized in that the preservative comprises any one or mixture of several of benzoic acid, sorbic acid and salts thereof.
9. The raw materials, the auxiliary materials and the proper amount of solvent according to the claims 1-5, wherein the essence comprises any one or more of but not limited to lemon essence, juicy peach essence, Hami melon essence, grape essence, miscellaneous fruit essence, blueberry essence, banana essence, strawberry essence and orange essence.
10. Raw materials, auxiliary materials and a proper amount of solvent according to claims 1-5, characterized in that the solvent comprises purified water, deionized water, distilled water.
11. The liquid oral preparation for treating children anorexia and monophagia as claimed in claim 1, wherein the preparation method comprises sugar-containing oral liquid preparation and sugar-free oral liquid preparation.
12. The process for preparing a sugar-containing oral liquid preparation according to claim 10, which comprises mixing the above raw materials, adjuvants and solvents of claim 2 or 3 in the following ratio;
12.1, taking taurine, adding a small amount of purified water for dissolving to obtain a taurine aqueous solution for later use;
12.2 taking the other 13 medicinal materials such as astragalus and the like, adding water for decocting twice, adding 10-12 times of water for the first time, decocting for 2-3 hours, adding 8-10 times of water for the second time, decocting for 1-2 hours, combining the decoction liquids of the two times, filtering, standing the filtrate for 20-40 hours, taking the supernatant for filtering, concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.2-1.3 at 55-60 ℃, and obtaining the extract of the medicinal materials such as the astragalus and the like for later use;
12.3 extracting the above radix astragali and other medicinal materials to obtain fluid extract, adding ethanol to make ethanol content 60-80%, stirring for 15-30 min, standing at 3-25 deg.C for 18-24 hr, collecting supernatant, filtering, recovering ethanol from filtrate until no ethanol smell exists, concentrating to obtain soft extract with relative density of 1.25-1.35 at 55-60 deg.C, and precipitating with ethanol to obtain soft extract;
12.4 taking the flavoring agent, the preservative and the essence, adding a small amount of purified water for dissolving, and filtering to obtain a dissolving solution of auxiliary materials such as the flavoring agent for standby;
12.5 taking the thick paste, adding taurine aqueous solution, correctant and other auxiliary material dissolved solutions, adding purified water to 70-80% of the preparation amount, stirring for dissolving, standing for 18-24 hours, filtering, adding purified water to the filtrate to the preparation amount, stirring for 15-30 minutes, filling and sterilizing to obtain the finished product.
13. The method for preparing the sugar-free oral liquid preparation according to claim 10, wherein the preparation method comprises the steps of taking the raw materials, auxiliary materials and solvents in the formula and the mixture ratio of 3 or 4, and preparing the raw materials, the auxiliary materials and the solvents according to the following method;
13.1, taking taurine, adding a small amount of purified water for dissolving to obtain a taurine aqueous solution for later use;
13.2 taking the rest 13 raw materials such as astragalus and the like, adding water for decocting twice, adding 10-12 times of water for the first time, decocting for 2-3 hours, adding 8-10 times of water for the second time, decocting for 1-2 hours, combining the decoctions for two times, filtering, standing the filtrate for 18-24 hours, taking the supernatant, filtering, and concentrating the filtrate under reduced pressure to obtain clear paste with the relative density of 1.2-1.3 at 55-60 ℃ to obtain the extract of the medicinal materials such as the astragalus and the like for later use;
13.3 extracting the above medicinal materials such as radix astragali, etc. to obtain fluid extract, adding ethanol to make ethanol content 60-75 deg.C, stirring for 30 min, standing at 5-7 deg.C for 18-24 hr, collecting supernatant, filtering, recovering ethanol from filtrate until no ethanol smell exists, concentrating to obtain soft extract with relative density of 1.25-1.35 at 55-60 deg.C, and precipitating with ethanol to obtain soft extract;
13.4 taking the flavoring agent, the preservative and the essence, adding a small amount of purified water for dissolving, filtering, and obtaining filtrate for later use;
13.5 taking the thick paste obtained by alcohol precipitation, adding the taurine aqueous solution and the filtrate, adding purified water to 70-80% of the preparation amount, stirring for 30 minutes, adding purified water to the preparation amount, stirring uniformly, filtering, filling, and performing damp-heat sterilization at 105 ℃ for 45 minutes to obtain the finished product.
14. The method according to claim 12 or 13, wherein the filtering in claim 11.2 or 12.2 is performed by using a 100-mesh 250-mesh stainless steel screen.
15. The method according to claim 12 or 13, wherein the filtration according to claim 11.3 or 12.3 is performed by using a sand filter stick or a ceramic filter stick or a filter felt having a pore size of 0.8 μm.
16. The method according to claim 12 or 13, wherein the filtration according to claim 11.4, 11.5, 12.4 or 12.5 is carried out with a microporous membrane having a pore size of 0.45 to 0.68 μm.
17. The method according to claim 12 or 13, wherein the sterilization is performed by moist heat sterilization at 105 ℃ for 45 minutes or moist heat sterilization at 121 ℃ for 25 minutes, according to claim 11.5 or 12.5.
18. The liquid oral preparation for treating children anorexia and monophagia as claimed in claim 1, further comprising oral liquid, suspension or syrup.
19. The liquid oral preparation for treating children anorexia, monophagia and other diseases as claimed in claim 1, wherein the liquid oral preparation can be further prepared into solid preparations such as granules, tablets and capsules.
20. The oral liquid preparation for treating children anorexia, monophagia and other diseases, as well as the preparation method and the application thereof according to claim 1, is characterized in that the application comprises the following components: can regulate spleen and stomach function, improve immunity, improve sub-health state of organism, and treat infantile anorexia, monophagia, malnutrition, diarrhea due to spleen deficiency, fever, and recurrent infection of respiratory tract and digestive tract.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911058036.4A CN110812455A (en) | 2019-11-01 | 2019-11-01 | A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911058036.4A CN110812455A (en) | 2019-11-01 | 2019-11-01 | A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110812455A true CN110812455A (en) | 2020-02-21 |
Family
ID=69552140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911058036.4A Pending CN110812455A (en) | 2019-11-01 | 2019-11-01 | A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110812455A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115779050A (en) * | 2022-12-09 | 2023-03-14 | 葵花药业集团(贵州)宏奇有限公司 | Chinese medicinal composition for regulating gene expression level and its application in preparing medicine |
CN115845005A (en) * | 2022-12-09 | 2023-03-28 | 葵花药业集团(贵州)宏奇有限公司 | Application of traditional Chinese medicine composition in adjusting expression level of PKA (protein kinase A) pathway-related protein of jejunum and preparing medicine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326355B1 (en) * | 1996-04-25 | 2001-12-04 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
CN1879821A (en) * | 2006-04-29 | 2006-12-20 | 贵州宏奇药业有限公司 | A method for preparing sugar-free granule with astragalus root, dendrobium stem and haw thorn fruit |
CN106938027A (en) * | 2017-02-27 | 2017-07-11 | 胡奖荣 | Treat the medicine of apositia |
-
2019
- 2019-11-01 CN CN201911058036.4A patent/CN110812455A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326355B1 (en) * | 1996-04-25 | 2001-12-04 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
CN1879821A (en) * | 2006-04-29 | 2006-12-20 | 贵州宏奇药业有限公司 | A method for preparing sugar-free granule with astragalus root, dendrobium stem and haw thorn fruit |
CN106938027A (en) * | 2017-02-27 | 2017-07-11 | 胡奖荣 | Treat the medicine of apositia |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115779050A (en) * | 2022-12-09 | 2023-03-14 | 葵花药业集团(贵州)宏奇有限公司 | Chinese medicinal composition for regulating gene expression level and its application in preparing medicine |
CN115845005A (en) * | 2022-12-09 | 2023-03-28 | 葵花药业集团(贵州)宏奇有限公司 | Application of traditional Chinese medicine composition in adjusting expression level of PKA (protein kinase A) pathway-related protein of jejunum and preparing medicine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112121144B (en) | Roxburgh rose composition and preparation method and application thereof | |
CN1519006A (en) | Prepared Chinese medicine for treating fastidium of wean caused by deficient spleen and food stasis | |
CN110812455A (en) | A liquid oral preparation for treating children anorexia and monophagia, and its preparation method and application | |
CN108686026B (en) | Licorice root and platycodon root granules for lung heat cough and preparation method thereof | |
CN105832991B (en) | Traditional Chinese medicine composition for treating gastritis | |
CN103784918A (en) | Medicine composition for treating regurgitation-induced quidding of equus animals | |
CN111643646A (en) | Traditional Chinese medicine preparation for preventing and treating new coronary pneumonia and preparation method and application thereof | |
CN116603041A (en) | A Chinese medicinal composition for treating dyspepsia and resisting helicobacter pylori | |
CN101254263A (en) | Compound Japanese polygala oral liquid and method of preparing the same | |
CN104940597A (en) | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition | |
CN110755601B (en) | Kidney bean lectin plant medicine composition for treating HIV/AIDS immune reconstruction defect and preparation method and application thereof | |
CN108567854A (en) | Join Ling oral liquid and preparation method thereof | |
CN103301244B (en) | Traditional Chinese medicinal preparation for treating infantile pneumonia and preparation method of traditional Chinese medicinal preparation | |
CN109091633B (en) | Composition for treating recurrent respiratory tract infection of children and preparation method and application thereof | |
CN110368469A (en) | Join glue stilbene particle drink | |
CN117100833B (en) | Traditional Chinese medicine composition for conditioning intestinal flora and preparation method and application thereof | |
CN108186874B (en) | A Chinese medicinal composition for treating diabetes | |
CN114259540B (en) | Traditional Chinese medicine composition for treating diabetes with syndrome of deficiency of both qi and yin and preparation method and application thereof | |
CN101991721B (en) | Shiqi expathy traditional Chinese medicine sugar-free granule | |
CN111514237B (en) | Traditional Chinese medicine composition for treating viral myocarditis and preparation method thereof | |
CN109820826B (en) | Anti-inflammatory traditional Chinese medicine granules and preparation method thereof | |
CN104435152A (en) | Traditional Chinese medicine agent with functions of tranquilizing and allaying excitement for treating stage I of hypertension and preparation method | |
CN110839896A (en) | Preparation method of ginseng instant food for improving type II diabetes symptoms | |
CN113908233A (en) | Traditional Chinese medicine composition for relieving defecation dysfunction caused by spinal cord injury | |
CN104510965A (en) | Traditional Chinese medicinal composition for treating child chronic gastritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200221 |
|
WD01 | Invention patent application deemed withdrawn after publication |